{"title":"Cannabis use disorder is a developmental disease","authors":"Alison Knopf","doi":"10.1002/cpu30875","DOIUrl":"https://doi.org/10.1002/cpu30875","url":null,"abstract":"<p>A recent study looked closely at the chronic use of marijuana by adolescents, and found that there is a causal connection to psychosis. In the study by veteran cannabis researcher Jasmin Hurd, M.D. and colleagues, the study, “The developmental trajectory to cannabis use disorder” (to be published in the May issue of the <i>American Journal of Psychiatry</i>), senior author Hurd, working with lead author Jess Hinckley, M.D, an adolescent psychiatrist at Mt. Sinai Hospital in New York City, looked at the many harms of cannabis use to young people who are still developing.</p>","PeriodicalId":22496,"journal":{"name":"The Brown University Child & Adolescent Psychopharmacology Update","volume":"26 7","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141298780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Information on semaglutide and compounding","authors":"Alison Knopf","doi":"10.1002/cpu30881","DOIUrl":"https://doi.org/10.1002/cpu30881","url":null,"abstract":"<p>Semaglutide belongs to a class of medications known as glucagon-like peptide-1 (GLP-1) receptor agonists. It mimics the GLP-1 hormone that is released in the gastrointestinal tract in response to eating. One role of GLP-1 is to prompt the body to produce more insulin, which reduces blood glucose (sugar). GLP-1 in higher amounts also interacts with the parts of the brain that reduce appetite and signal a feeling of fullness.</p>","PeriodicalId":22496,"journal":{"name":"The Brown University Child & Adolescent Psychopharmacology Update","volume":"26 7","pages":"8"},"PeriodicalIF":0.0,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141298430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Childhood maltreatment linked to subsequent mental disorders and suicides","authors":"Alison Knopf","doi":"10.1002/cpu30879","DOIUrl":"https://doi.org/10.1002/cpu30879","url":null,"abstract":"","PeriodicalId":22496,"journal":{"name":"The Brown University Child & Adolescent Psychopharmacology Update","volume":"26 7","pages":"6-7"},"PeriodicalIF":0.0,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141298778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Rapid initiation protocol for naltrexone for OUD","authors":"Alison Knopf","doi":"10.1002/cpu30877","DOIUrl":"https://doi.org/10.1002/cpu30877","url":null,"abstract":"<p>Your idea of “rapid” may be different from that of the National Institute on Drug Abuse (NIDA), which funded a study showing that it is possible to start patients on injectable, extended-release naltrexone (trade name Vivitrol) within five to seven days after they stop opioid use — and called that “rapid initiation.” But it's all relative. The standard treatment method was within 10–15 days, according to NIDA. The new finding shortens that painful period.</p>","PeriodicalId":22496,"journal":{"name":"The Brown University Child & Adolescent Psychopharmacology Update","volume":"26 7","pages":"5-6"},"PeriodicalIF":0.0,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141298776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Short sleep and inflammation linked to increased rate of psychosis","authors":"Alison Knopf","doi":"10.1002/cpu30876","DOIUrl":"https://doi.org/10.1002/cpu30876","url":null,"abstract":"<p>Mechanisms linking childhood short sleep duration with later psychosis are not well known, but inflammation has recently been suggested as a mediating factor. Researchers looked at this closely for a recent study using longitudinal data from a major cohort study, and found that there was an association between elevated interleukin in childhood and psychosis at age 24.</p>","PeriodicalId":22496,"journal":{"name":"The Brown University Child & Adolescent Psychopharmacology Update","volume":"26 7","pages":"4-5"},"PeriodicalIF":0.0,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141298722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"NIDA starts new study, at infancy, complementary to ABCD","authors":"Alison Knopf","doi":"10.1002/cpu30880","DOIUrl":"https://doi.org/10.1002/cpu30880","url":null,"abstract":"<p>The National Institute on Drug Abuse (NIDA) has a new study underway, designed to look at how environmental exposures, especially to opioids and other drugs, affect infant and child brain development. The HEALthy Brain and Child Development (HBCD) Study recruits pregnant women to study their infants from birth. NIDA is conducting this study as part of the multi-agency Helping to End Addiction Long-term (HEAL) Initiative of the National Institutes of Health.</p>","PeriodicalId":22496,"journal":{"name":"The Brown University Child & Adolescent Psychopharmacology Update","volume":"26 7","pages":"7"},"PeriodicalIF":0.0,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141298779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Vaping posts on Instagram violate federal and online policies, research finds","authors":"Alison Knopf","doi":"10.1002/cpu30878","DOIUrl":"https://doi.org/10.1002/cpu30878","url":null,"abstract":"","PeriodicalId":22496,"journal":{"name":"The Brown University Child & Adolescent Psychopharmacology Update","volume":"26 7","pages":"6"},"PeriodicalIF":0.0,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141298777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Marijuana taken off the illegal list?","authors":"Alison Knopf","doi":"10.1002/cpu30874","DOIUrl":"https://doi.org/10.1002/cpu30874","url":null,"abstract":"<p>Parents are rightly concerned about the increased use of high potency cannabis, which has been linked in several research reports to first episode psychosis. Consider the word “first” — psychosis can be a lifelong chronic condition. Many articles in this publication have highlighted the connection.</p>","PeriodicalId":22496,"journal":{"name":"The Brown University Child & Adolescent Psychopharmacology Update","volume":"26 7","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141298431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"FDA sends warning letter about e cigarettes","authors":"Alison Knopf","doi":"10.1002/cpu30872","DOIUrl":"https://doi.org/10.1002/cpu30872","url":null,"abstract":"<p>In April, the Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that Ram Goods LLC sells and/or distributes electronic nicotine delivery system (ENDS) products to customers in the United States.</p>","PeriodicalId":22496,"journal":{"name":"The Brown University Child & Adolescent Psychopharmacology Update","volume":"26 6","pages":"7-8"},"PeriodicalIF":0.0,"publicationDate":"2024-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140906992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}